News & Events

News Releases
NEW YORK , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics , Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, presented updated data from multiple ELZONRIS TM (tagraxofusp; SL-401) clinical trials at

Additional Formats

NEW YORK , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics , Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted four upcoming ELZONRIS™ (tagraxofusp; SL-401) presentations, including an oral

Additional Formats

NEW YORK , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced today that the European Medicines Agency (EMA) has granted accelerated assessment

Additional Formats

NEW YORK , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced today that data from the Phase 2 trial of SL-701 in patients with second-line

Additional Formats

NEW YORK , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced today financial results for the quarter ended September 30, 2018 .

Additional Formats

NEW YORK , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS™ (tagraxofusp; SL-401), a novel targeted therapeutic directed to CD123,

Additional Formats

NEW YORK , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical data from its SL-701 and SL-801 trials have been selected for presentation, including an oral

Additional Formats

NEW YORK , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein , M.D., Stemline’s CEO, is scheduled to present at two upcoming investor conferences: The

Additional Formats

NEW YORK , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein , M.D., Stemline’s CEO, will present at the H.C.

Additional Formats

NEW YORK , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein , M.D., Stemline’s CEO, will present at the 2018 Wedbush PacGrow Healthcare Conference on

Additional Formats

Displaying 1 - 10 of 29
Upcoming Events
More events are coming soon.